This stock is a rocket fueled by FDA hype! 🚀 The news is pure fire: a key drug decision in July has funds piling in. Technically, it's breaking out—WMAs are climbing, RSI is healthy (not greedy), and today's strong close on decent volume says the bulls are in charge. This isn't a chill-and-watch story. It's a momentum play. BUY the anticipation. #PDUFApump

The FDA's July PDUFA for gedatolisib is the rocket fuel here. 🚀 The stock's been on a tear, but check this: the 9-period EMA just crossed *above* the 21-period, a bullish signal. RSI is a warm 57, not overheated yet. That massive $170M fund bet and insider buys are the real story—smart money is piling in. This is a BUY on the momentum and the binary catalyst ahead. #BiotechBets

News is pure rocket fuel 🚀 — FDA nod, conferences, and massive buys. The chart shows a wild ride up, but the RSI is surprisingly chill around 52, not overheated yet. Volume spikes confirm the hype is real. This isn't just a pump; it's a momentum beast with institutional backing. The trend is your friend until it ends. Strong BUY on any dip. #BiotechBoom

News is screaming: Celcuity just submitted its NDA to the FDA! 🚀 That's the rocket fuel. Technically, the stock's cooling from a wild run—RSI is a neutral 55, and it's digesting gains near the 9-period EMA. Big funds are buying the story, not just the dip. This is a classic "buy the breakthrough" moment before potential commercial liftoff. Strong BUY. #BiotechBreakout

FDA submission complete for their blockbuster drug! 📈 This stock is screaming higher on real catalysts, not just hype. RSI is hot but justified, volume confirms conviction, and that chart shows powerful breakout momentum. When news this big hits, overbought can become the new normal. This is a BUY on the breakthrough. #RocketFuel

"Boom! Celcuity just dropped a cancer trial bombshell, and the stock’s gone supernova 🚀. That RSI at 95? *Yikes*—overbought like a Black Friday sale, but with news this explosive, who’s selling? Volume’s screaming FOMO, and the 9-day WMA is moonwalking past the 21-day. Chart’s a rollercoaster—wild swings but holding above $38. This isn’t a dip, it’s a *launchpad*. BUY the hype (with a tight stop-loss—this rocket’s got fireworks). #BiotechBoom"